|A UK collaboration, led by UK optical imaging company Michelson Diagnostics (MDL), has produced its
first Optical Coherence Tomography (OCT) images at the new wavelength of 1 micron, providing
improved resolution and contrast.|
To date, most imaging of skin tissue has been done at the longer wavelength of 1.3 µm. The shorter
wavelength of 1 µm requires development of new laser and optical technology.[+]
Leading OCT researcher Professor Wolfgang Drexler, Director of Research at the University of Cardiff
School of Optometry and Vision Science, said We believe that images acquired at 1ìm wavelength will
offer improved contrast and resolution that will help clinicians to distinguish between healthy and
The initial images of healthy skin tissue, obtained with an MDL OCT Microscope converted to 1 µm,
appear to support this view. Features such as capillaries and the boundaries between tissue layers are
more clearly defined.
Further work in 2009 will concentrate on increasing the laser power, for more depth penetration, and on
evaluating and analysing images of cancerous tissue taken with the new probe.
The collaboration is between MDL, University of Cardiff, Gloucestershire Hospitals NHS Foundation
Trust, National Physical Laboratory, semiconductor specialist Kamelian and medical imaging systems
The project, funded in 2007 by the UKs Technology Strategy Board, is titled OMICRON, and is focused
on development of an in-vivo imaging probe, using OCT, to obtain high resolution sub-surface images of
cancerous tissue, operating at the new, untried wavelength of 1µm.
Clinicians frequently take biopsy samples of tissue for laboratory analysis by pathologists when
diagnosing, assessing, treating and monitoring cancer. This can be inefficient, expensive and time
consuming. The biopsy may be poorly targeted on the tumour, and results from the analysis can take
weeks to come back.
Dr Nick Stone, Head of Biophotonics at Gloucestershire Hospitals NHS Foundation Trust, added OCT
scanning has the exciting potential of both guiding and reducing the dependence on biopsies, which
could speed up cancer diagnosis and treatment, reducing the pressure on overloaded pathology
departments, and improve outcomes from cancer surgery.
For further information and press enquiries contact:
Jon Holmes, Chief Executive Officer, Michelson Diagnostics Ltd
Michelson Diagnostics Ltd, 11A Grays Farm Production Village, Orpington, Kent, BR5 3BD, UK
+44 (0) 208 308 1695
Michelson Diagnostics Ltd
Michelson Diagnostics Ltd is the UKs leading independent manufacturer and developer of Optical
Coherence Tomography (OCT) medical imaging equipment. Founded in 2006, it is based in SE London,
UK. The company has developed a highly innovative multi-beam OCT technology which delivers higher
resolution, greater contrast images.